Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 11/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | ATR | Q13535 | 3/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613865 | 1.00 | MTOR (0.44) | MTORPIK3CAPIK3CDATRCHEK1 | |
| SCHEMBL1612707 | 0.87 | PIK3CA (0.46) | MTORPIK3CAPIK3CDATRPDE4D | |
| SCHEMBL1612708 | 0.87 | PIK3CA (0.46) | MTORPIK3CAPIK3CDATRPDE4D | |
| SCHEMBL1612580 | 0.86 | MTOR (0.42) | MTORPIK3CAPIK3CDATRPDE4D | |
| SCHEMBL1612578 | 0.86 | MTOR (0.42) | MTORPIK3CAPIK3CDATRPDE4D | |
| SCHEMBL1611489 | 0.82 | MTOR (0.43) | MTORPIK3CAPIK3CDATRPDE4D | |
| SCHEMBL1611493 | 0.82 | MTOR (0.43) | MTORPIK3CAPIK3CDATRPDE4D | |
| SCHEMBL1613240 | 0.81 | MTOR (0.47) | MTORPIK3CAPIK3CDATRPDE4D | |
| SCHEMBL1613242 | 0.81 | MTOR (0.47) | MTORPIK3CAPIK3CDATRPDE4D | |
| SCHEMBL2674328 | 0.79 | MTOR (0.46) | MTORPIK3CAPIK3CDATRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2498780-B1 | N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-09-07 | — | — | EP | disclosed |
| EP-2498780-B1 | N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-09-07 | — | — | EP | disclosed |
| US-8288381-B2 | N-9 substituted purine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288381-B2 | N-9 substituted purine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288381-B2 | N-9 substituted purine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110086841-A1 | N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086841-A1 | N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086841-A1 | N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086841-A1 | N-9 SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ADORA3, ADORA2A, ADORA2B | MTOR 3111/4885PIK3CA 1026/4885PIK3CD 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.